亚辉龙股价涨5.27%，华宝基金旗下1只基金位居十大流通股东，持有1141.85万股浮盈赚取879.23万元

Group 1 - The core viewpoint of the news is that Aihuilong's stock price increased by 5.27%, reaching 15.39 CNY per share, with a total market capitalization of 8.779 billion CNY as of the report date [1] - Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescent immunoassay methods [1] - The company's revenue composition includes 58.57% from self-produced reagents (non-COVID products), 12.60% from self-produced consumables (non-COVID products), and 11.92% from self-produced instruments (non-COVID products) [1] Group 2 - Huabao Zhongzheng Medical ETF (512170) is among the top ten circulating shareholders of Aihuilong, having increased its holdings by 171,400 shares in the second quarter, now holding 11.4185 million shares, which is 2% of the circulating shares [2] - The fund has achieved a year-to-date return of 14.75% and a one-year return of 6.63%, ranking 3345 out of 4218 and 3530 out of 3878 in its category, respectively [2]